|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,910.00 GBX | +2.35% |
|
+3.25% | +0.87% |
| 06-24 | Health Care Up on Rotation Into Beaten-Down Sectors -- Health Care Roundup | DJ |
| 06-24 | US military requires flu vaccine for some after outbreak in Texas training center | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 284,060 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -1.3% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 303,305 | 296,065 | 288,061 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -2.53% | -2.39% | -2.7% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 23x | 20x | 17.3x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 5.34x | 4.61x | 3.76x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1x | 1.4x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.49x | 4.23x | 3.97x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.79x | 4.41x | 4.03x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 13.6x | 12.1x | 10.8x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 14.3x | 12.6x | 11.1x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 29.1x | 21.5x | 18.9x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.44% | 4.64% | 5.28% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.337 | 3.524 | 3.659 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.82% | 1.92% | 2% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.979 | 9.145 | 10.61 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 41.8% | 38.5% | 34.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,321 | 67,157 | 71,556 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,337 | 24,470 | 26,751 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,241 | 23,587 | 25,911 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,488 | 14,137 | 16,137 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,245 | 12,005 | 4,001 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 183.15 | 183.15 | 183.15 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,550,996 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.48x | 4.7x | 13.31x | 1.86% | 278B | |
| 32.26x | 11.78x | 24.17x | 0.62% | 987B | |
| 25.55x | 5.89x | 16.01x | 2.23% | 576B | |
| 29.14x | 6.97x | 14.27x | 2.95% | 415B | |
| 17.33x | 4.31x | 10.6x | 3.08% | 320B | |
| 21.11x | 5.46x | 13.24x | 2.93% | 279B | |
| 13.65x | 5.05x | 10.4x | 3.69% | 208B | |
| 22.56x | 6.05x | 10.56x | 2.91% | 187B | |
| -44.81x | 5.41x | 29.83x | 2.6% | 155B | |
| 11.56x | 3.07x | 7.46x | 7.09% | 141B | |
| Average | 15.08x | 5.87x | 14.99x | 2.99% | 354.61B | |
| Weighted average by Cap. | 22.01x | 7.21x | 16.81x | 2.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
